These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

440 related items for PubMed ID: 29412643

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Cell Wall Associated Factors of Mycobacterium tuberculosis as Major Virulence Determinants: Current Perspectives in Drugs Discovery and Design.
    Singh G, Kumar A, Maan P, Kaur J.
    Curr Drug Targets; 2017 Nov 30; 18(16):1904-1918. PubMed ID: 28699515
    [Abstract] [Full Text] [Related]

  • 6. [Development of antituberculous drugs: current status and future prospects].
    Tomioka H, Namba K.
    Kekkaku; 2006 Dec 30; 81(12):753-74. PubMed ID: 17240921
    [Abstract] [Full Text] [Related]

  • 7. The Mycobacterium tuberculosis Cell Wall: An Alluring Drug Target for Developing Newer Anti-TB Drugs-A Perspective.
    Chauhan M, Barot R, Yadav R, Joshi K, Mirza S, Chikhale R, Srivastava VK, Yadav MR, Murumkar PR.
    Chem Biol Drug Des; 2024 Sep 30; 104(3):e14612. PubMed ID: 39237482
    [Abstract] [Full Text] [Related]

  • 8. Discovery of novel lysine ɛ-aminotransferase inhibitors: An intriguing potential target for latent tuberculosis.
    Devi PB, Sridevi JP, Kakan SS, Saxena S, Jeankumar VU, Soni V, Anantaraju HS, Yogeeswari P, Sriram D.
    Tuberculosis (Edinb); 2015 Dec 30; 95(6):786-794. PubMed ID: 26299907
    [Abstract] [Full Text] [Related]

  • 9. Design, synthesis and investigation on the structure-activity relationships of N-substituted 2-aminothiazole derivatives as antitubercular agents.
    Pieroni M, Wan B, Cho S, Franzblau SG, Costantino G.
    Eur J Med Chem; 2014 Jan 24; 72():26-34. PubMed ID: 24333612
    [Abstract] [Full Text] [Related]

  • 10. New approaches to target the mycolic acid biosynthesis pathway for the development of tuberculosis therapeutics.
    North EJ, Jackson M, Lee RE.
    Curr Pharm Des; 2014 Jan 24; 20(27):4357-78. PubMed ID: 24245756
    [Abstract] [Full Text] [Related]

  • 11. Potential Drug Targets in Mycobacterial Cell Wall: Non-Lipid Perspective.
    Das S, Hameed S, Fatima Z.
    Curr Drug Discov Technol; 2020 Jan 24; 17(2):147-153. PubMed ID: 29875004
    [Abstract] [Full Text] [Related]

  • 12. Mycobacterium Tuberculosis (MTB) GyrB inhibitors: An attractive approach for developing novel drugs against TB.
    Chaudhari K, Surana S, Jain P, Patel HM.
    Eur J Med Chem; 2016 Nov 29; 124():160-185. PubMed ID: 27569197
    [Abstract] [Full Text] [Related]

  • 13. Mycobacterial tuberculosis Enzyme Targets and their Inhibitors.
    Saxena AK, Singh A.
    Curr Top Med Chem; 2019 Nov 29; 19(5):337-355. PubMed ID: 30806318
    [Abstract] [Full Text] [Related]

  • 14. Delamanid: From discovery to its use for pulmonary multidrug-resistant tuberculosis (MDR-TB).
    Liu Y, Matsumoto M, Ishida H, Ohguro K, Yoshitake M, Gupta R, Geiter L, Hafkin J.
    Tuberculosis (Edinb); 2018 Jul 29; 111():20-30. PubMed ID: 30029909
    [Abstract] [Full Text] [Related]

  • 15. Current Advances in Antitubercular Drug Discovery: Potent Prototypes and New Targets.
    Dos Santos Fernandes GF, Jornada DH, de Souza PC, Chin CM, Pavan FR, Dos Santos JL.
    Curr Med Chem; 2015 Jul 29; 22(27):3133-61. PubMed ID: 26282941
    [Abstract] [Full Text] [Related]

  • 16. High throughput crystallography of TB drug targets.
    Murillo AC, Li HY, Alber T, Baker EN, Berger JM, Cherney LT, Cherney MM, Cho YS, Eisenberg D, Garen CR, Goulding CW, Hung LW, Ioerger TR, Jacobs WR, James MN, Kim C, Krieger I, Lott JS, Sankaranarayanan R, Segelke BW, Terwilliger TC, Wang F, Wang S, Sacchettini JC.
    Infect Disord Drug Targets; 2007 Jun 29; 7(2):127-39. PubMed ID: 17970224
    [Abstract] [Full Text] [Related]

  • 17. Identification of Mycobacterium tuberculosis CtpF as a target for designing new antituberculous compounds.
    Santos P, Lopez-Vallejo F, Ramírez D, Caballero J, Mata Espinosa D, Hernández-Pando R, Soto CY.
    Bioorg Med Chem; 2020 Feb 01; 28(3):115256. PubMed ID: 31879181
    [Abstract] [Full Text] [Related]

  • 18. Lipid transport in Mycobacterium tuberculosis and its implications in virulence and drug development.
    Bailo R, Bhatt A, Aínsa JA.
    Biochem Pharmacol; 2015 Aug 01; 96(3):159-67. PubMed ID: 25986884
    [Abstract] [Full Text] [Related]

  • 19. Discovery of antitubercular 2,4-diphenyl-1H-imidazoles from chemical library repositioning and rational design.
    Pieroni M, Wan B, Zuliani V, Franzblau SG, Costantino G, Rivara M.
    Eur J Med Chem; 2015 Jul 15; 100():44-9. PubMed ID: 26071857
    [Abstract] [Full Text] [Related]

  • 20. Screening of antitubercular compound library identifies novel ATP synthase inhibitors of Mycobacterium tuberculosis.
    Kumar S, Mehra R, Sharma S, Bokolia NP, Raina D, Nargotra A, Singh PP, Khan IA.
    Tuberculosis (Edinb); 2018 Jan 15; 108():56-63. PubMed ID: 29523328
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 22.